A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids

A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids

Abstract Background Patients with asthma uncontrolled on inhaled corticosteroids may benefit from umeclidinium (UMEC), a long-acting muscarinic antagonist. Methods This Phase IIb, double-blind study included patients with reversible, uncontrolled/partially-controlled asthma for ≥6 months, receiving...

Full description

Bibliographic Details
Main Authors: Edward Kerwin, Steven Pascoe, Zelie Bailes, Robert Nathan, David Bernstein, Ronald Dahl, Robyn von Maltzahn, Kevin Robbins, Andrew Fowler, Laurie Lee
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Respiratory Research
Subjects:
Asthma
Forced expiratory volume in 1 s
Inhaled corticosteroid
Long-acting muscarinic antagonist
Umeclidinium
Online Access:http://link.springer.com/article/10.1186/s12931-020-01400-5

Internet

http://link.springer.com/article/10.1186/s12931-020-01400-5

Similar Items